2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...

Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

Amgen (NASDAQ:AMGN) today issued the following statement on the MariTide (maridebart cafraglutide, formerly AMG 133) Phase 1 data.

Discover why Amgen is a reliable wealth compounder with strong Q3 results, a promising pipeline, debt reduction, and ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Wednesday’s business headlines INDIANAPOLIS (WISH) — Here is a look at Wednesday’s business headlines with Jane ...

Amgen, a global biotechnology leader highlighting profound research and development capabilities and biomanufacturing, showcases its latest achievements in the field of innovative medicines under the ...

At the CIIE, Amgen brings six innovative products-focusing on cardiovascular, bone health, oncology, inflammation and rare diseases-each precisely tailored to the unmet needs of Chinese patients.

These are independent reviews of the products mentioned ... So scientists at Amgen took another route: They developed a drug, Imdelltra, that prompts the immune system’s T cells, which typically ...

Discover how Amgen is achieving a fully automated enterprise through strategic partnerships with Cognizant and UiPath to enhance efficiency.

“Amgen Inc. (NASDAQ:AMGN) is a large cap global biotech company with a diverse portfolio of marketed and pipeline products. Amgen’s discovery pipeline had led the company to broaden its focus ...